Meningococcal capsular polysaccharides conjugated to carrier proteins (MCV)

Meningococcal capsular polysaccharides conjugated to carrier proteins are the primary antigenic components of modern conjugate vaccines designed to prevent invasive disease caused by Neisseria meningitidis (CDC, 2023) [1]. These vaccines target specific bacterial serogroups, most commonly A, C, W-135, and Y, which are major causes of bacterial meningitis and septicemia worldwide (WHO, 2023) [2]. By chemically linking these polysaccharides to a carrier protein, such as CRM197 or tetanus toxoid, the vaccine overcomes the limitations of pure polysaccharide vaccines, which fail to induce immunological memory or protect infants (Pollard et al., 2009) [4]. The resulting conjugate complex triggers a T-cell dependent immune response, leading to the production of high-affinity IgG antibodies and the establishment of long-term B-cell memory (StatPearls, 2023) [3]. These antibodies facilitate the destruction of the bacteria through complement-mediated lysis and opsonophagocytosis. This target is crucial for public health, particularly in adolescent and pediatric populations, to reduce carriage and provide herd immunity. References: [1] CDC (2023) https://www.cdc.gov/vaccines/vpd/mening/hcp/index.html [2] WHO (2023) https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis [3] StatPearls (2023) https://www.ncbi.nlm.nih.gov/books/NBK538214/ [4] Pollard et al. (2009) https://pubmed.ncbi.nlm.nih.gov/11587808/

Other names

Meningococcal conjugate vaccineMenACWYMenC conjugateNeisseria meningitidis capsular polysaccharide-protein conjugateMCV4

Induction of a T-cell dependent immune response through the conjugation of bacterial capsular polysaccharides to carrier proteins, which facilitates high-affinity IgG antibody production and immunological memory (StatPearls, 2023) [3].